SequelSEC

Exousia Bio, Inc. LMMY

Services-Educational Services · CIK 0001939937 · Fiscal year ends 0531

AnnualQuarterlyTTM
Revenue
$3.75K
Fiscal year ended 2025-05-31
Operating income
Unavailable
Fiscal year ended 2025-05-31
Free cash flow
Unavailable
Fiscal year ended 2025-05-31

Exousia Bio, Inc. (LMMY) reported revenue of $3.75K and net income of $51.40K for the fiscal year ended 2025-05-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from Exousia Bio, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Educational Services.

Income

Exousia Bio, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-05-312024-05-312023-05-31
Revenue$3.75K$11.50K$0
Cost of revenue$7.25K$9.67K$0
Gross profit-$3.50K$1.83K$0
Operating incomeUnavailableUnavailable-$56.42K
Net income$51.40K-$25.81K-$56.42K
Research & developmentUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 7.78Mshares 7.78Mshares 5.69M
Pretax income$51.40K-$25.81K-$56.42K
Income tax expense$0$0$0
Diluted EPS$0.00$0.00$0.00
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$28.38K$28.08K$56.42K
Selling & marketingUnavailableUnavailableUnavailable

Balance

Exousia Bio, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-05-312024-05-312023-05-31
Cash & equivalentsUnavailableUnavailable$7.86K
Total assets$0$27.45K$37.04K
Current assets$0$12.96K$7.86K
Total liabilities$0$82.35K$66.13K
Current liabilities$0$14.17K$3.61K
Total equity incl. NCI$0-$54.90K-$29.09K
Temporary (mezzanine) equityUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable
Accounts receivable$0$11.50K$0
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$0UnavailableUnavailable

Cash flow

Exousia Bio, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-05-312024-05-312023-05-31
Operating cash flow-$4.53K-$12.48K-$38.11K
Capital expendituresUnavailableUnavailableUnavailable
Investing cash flow$0$0$0
Financing cash flow$3.50K$5.66K$35.86K
Net change in cashUnavailableUnavailableUnavailable
Stock-based compensationUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable

Derived

Exousia Bio, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-05-312024-05-312023-05-31
Free cash flowUnavailableUnavailableUnavailable
Gross margin-93.4%15.9%Unavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratioUnavailable0.91x2.18x
Revenue YoY growth-67.4%UnavailableUnavailable
Net margin1370.5%-224.4%Unavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rate0.0%UnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LMMY in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-06-16View SEC filing
10-Q · Filed 2026-03-17View SEC filing
10-Q · Filed 2025-11-17View SEC filing
10-K · Filed 2025-10-17View SEC filing
10-Q · Filed 2025-04-24View SEC filing
10-Q · Filed 2025-01-10View SEC filing

Companies in the same industry

AMBO APEI BOXL BRWC BSAA CHGG CVSA DWAY GHC KIDZ KPEA LAUR

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.